PMID- 20697984
OWN - NLM
STAT- MEDLINE
DCOM- 20110307
LR  - 20220317
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 11
IP  - 3
DP  - 2010 Sep
TI  - Formulation and in vitro characterization of Eudragit(R) L100 and Eudragit(R) 
      L100-PLGA nanoparticles containing diclofenac sodium.
PG  - 1250-6
LID - 10.1208/s12249-010-9489-6 [doi]
AB  - The aim of this study was to formulate and characterize Eudragit(R) L100 and 
      Eudragit(R) L100-poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing 
      diclofenac sodium. Diclofenac generates severe adverse effects with risks of 
      toxicity. Thus, nanoparticles were prepared to reduce these drawbacks in the 
      present study. These nanoparticles were evaluated for surface morphology, 
      particle size and size distribution, percentage drug entrapment, and in vitro 
      drug release in pH 6.8. The prepared nanoparticles were almost spherical in 
      shape, as determined by atomic force microscopy. The nanoparticles with varied 
      size (241-274 nm) and 25.8-62% of entrapment efficiency were obtained. The 
      nanoparticles formulations produced the release profiles with an initial burst 
      effect in which diclofenac sodium release ranged between 38% and 47% within 4 h. 
      The extent of drug release from Eudragit(R) L100 nanoparticles was up to 92% at 12 
      h. However, Eudragit(R)/PLGA nanoparticles showed an initial burst release followed 
      by a slower sustained release. The cumulative release at 72 h was 56%, 69%, and 
      81% for Eudragit(R)/PLGA (20:80), Eudragit(R)/PLGA (30:70) and Eudragit(R)/PLGA (50:50) 
      nanoparticles, respectively. The release profiles and encapsulation efficiencies 
      depended on the amount of Eudragit in the blend. These data demonstrated the 
      efficacy of these nanoparticles in sustaining the diclofenac sodium release 
      profile.
FAU - Cetin, Meltem
AU  - Cetin M
AD  - Department of Pharmaceutical Technology, Faculty of Pharmacy, Ataturk University, 
      25240, Erzurum, Turkey. melcetin@hotmail.com
FAU - Atila, Alptug
AU  - Atila A
FAU - Kadioglu, Yucel
AU  - Kadioglu Y
LA  - eng
PT  - Journal Article
DEP - 20100810
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Nanocapsules)
RN  - 0 (Polymethacrylic Acids)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 25086-15-1 (methylmethacrylate-methacrylic acid copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/chemistry
MH  - Delayed-Action Preparations/*chemical synthesis
MH  - Diclofenac/administration & dosage/*chemistry
MH  - Diffusion
MH  - Drug Compounding/methods
MH  - Lactic Acid/*chemistry
MH  - Nanocapsules/*chemistry/ultrastructure
MH  - Polyglycolic Acid/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Polymethacrylic Acids/*chemistry
PMC - PMC2974120
EDAT- 2010/08/11 06:00
MHDA- 2011/03/08 06:00
PMCR- 2011/08/10
CRDT- 2010/08/11 06:00
PHST- 2009/07/10 00:00 [received]
PHST- 2010/07/23 00:00 [accepted]
PHST- 2010/08/11 06:00 [entrez]
PHST- 2010/08/11 06:00 [pubmed]
PHST- 2011/03/08 06:00 [medline]
PHST- 2011/08/10 00:00 [pmc-release]
AID - 9489 [pii]
AID - 10.1208/s12249-010-9489-6 [doi]
PST - ppublish
SO  - AAPS PharmSciTech. 2010 Sep;11(3):1250-6. doi: 10.1208/s12249-010-9489-6. Epub 
      2010 Aug 10.